The End of High Cholesterol? The First Oral PCSK9 Drug Could Change Heart Medicine Forever - Dr. Norman Lepor, MD - Founder and Director, National Heart Institute
Heart disease remains the leading cause of death worldwide, and one of its most important modifiable risk factors is elevated LDL cholesterol - the so-called "bad cholesterol." While statins have transformed cardiovascular care for decades, and newer therapies like injectable PCSK9 inhibitors have provided additional options, millions of patients still struggle to achieve recommended LDL cholesterol targets.
In fact, despite the availability of effective therapies, roughly seventy percent of patients receiving cholesterol-lowering treatment still fail to reach guideline-recommended LDL cholesterol levels. The reasons are complex - from biology and treatment intensity to adherence and convenience - but the result is the same: preventable heart attacks, strokes, and cardiovascular deaths continue to occur.
Now, a new chapter is beginning. Following years of clinical development, the FDA has approved LIPFENDRA™ (enlicitide), the first oral PCSK9 inhibitor, introducing an entirely new approach to LDL cholesterol reduction ( https://www.lipfendra.com/ ).
Joining us today is someone uniquely qualified to help us understand what this approval means for physicians and patients.
Dr. Norman Lepor, MD is Founder and Director of the National Heart Institute ( https://nationalheartinstitute.org/about/meet-our-team ), Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, and an Attending Cardiologist at the Smidt Heart Institute at Cedars-Sinai ( https://www.cedars-sinai.org/provider/norman-lepor-106852.html ).
A graduate of Johns Hopkins School of Medicine, Dr. Lepor has spent more than four decades advancing cardiovascular medicine through patient care, education, and clinical research. He has served as principal investigator on more than sixty clinical trials, authored dozens of influential scientific publications, and has been recognized by U.S. News & World Report as one of America's leading cardiologists. Throughout his career he has also been a champion for women's cardiovascular health and improving access to cutting-edge care for underserved populations.
Today we'll discuss why LDL cholesterol remains such a difficult public health challenge, what we've learned over the past three decades of lipid management, how oral PCSK9 inhibition works, and what this newly approved therapy may mean for the future of preventing heart attacks and strokes.
Podden och tillhörande omslagsbild på den här sidan tillhör
Ira Pastor. Innehållet i podden är skapat av Ira Pastor och inte av,
eller tillsammans med, Poddtoppen.
